RDHL

RedHill Biopharma

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$28.9M

Burn Rate (Qtr)

$4.2M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

RDHL

BPIQ_Logo_RGB-01.jpg

Company Profile

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.

RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.

RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.

RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Recent Posts

See what the community is saying - click to see full post.

RDHL - Opaganib COVID-19 Study Passes Second Independent Committee Review

RDHL - Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib

RDHL - Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study